Solid Biosciences Inc.
SLDB Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$6.19
KIRA · Stoqly’s AI analyst, in plain words
- Solid Biosciences Inc. lost $174M in fiscal 2025.
- Free cash flow was −$157M in fiscal 2025, — of revenue.
Market cap
$889M
P/E
—
Revenue
—
Net income
−$174M
Free cash flow
−$157M
Operating margin
—
Solid Biosciences Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$174M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Solid Biosciences Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Solid Biosciences Inc.
- CIK
- 0001707502
Solid Biosciences Inc. · SLDB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $13.6M | $8.1M | — | — | — |
| Revenue growth | — | −40.6% | — | — | — |
| Operating margin | −530.5% | −1,315.2% | — | — | — |
| Net income | −$72.2M | −$86.0M | −$96.0M | −$125M | −$174M |
| Net margin | −530.0% | −1,062.3% | — | — | — |
| Diluted EPS | −$10.14 | −$10.10 | −$4.83 | −$3.06 | −$1.99 |
| Cash | |||||
| Cash from operations | −$77.8M | −$98.0M | −$94.2M | −$100M | −$156M |
| Capital expenditure | $1.3M | $3.0M | $1.5M | $0.7M | $1.2M |
| Free cash flow | −$79.0M | −$101M | −$95.7M | −$101M | −$157M |
| FCF margin | −580.4% | −1,247.7% | — | — | — |
| Share count change | 105.6% | 19.6% | 133.6% | 105.3% | 114.4% |
| Debt and strength | |||||
| Cash and short-term investments | $208M | $214M | $124M | $149M | $188M |
| Shareholders' equity | $208M | $212M | $126M | $137M | $180M |
| Current ratio | 9.4x | 9.8x | 8.9x | 5.2x | 6.1x |
| Interest coverage | — | — | −236.9x | −381.6x | — |
| Returns and quality | |||||
| Return on equity | −42.4% | −41.0% | −56.8% | −94.6% | −109.9% |
| Return on tangible equity | −34.7% | −40.6% | −75.9% | −90.9% | −96.8% |
| Piotroski F-score | 3 | 1 | — | — | — |
| Altman Z'' | 5.9 | −0.3 | −9.2 | −10.9 | −10.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.7M
7 insiders
Of sales under plans
99%
$2.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Solid Biosciences Inc. · SLDB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.19 a share, the company is worth $889M.
Source: SEC EDGAR XBRL filings (CIK 0001707502). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.